1
|
Györi GP, Pereyra D, Rumpf B, Hackl H, Köditz C, Ortmayr G, Reiberger T, Trauner M, Berlakovich GA, Starlinger P. The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation. Hepatology 2020; 72:584-594. [PMID: 31773739 PMCID: PMC7497135 DOI: 10.1002/hep.31047] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Accepted: 11/07/2019] [Indexed: 12/18/2022]
Abstract
BACKGROUND AND AIMS The Model for End-Stage Liver Disease (MELD) is used for clinical decision-making and organ allocation for orthotopic liver transplantation (OLT) and was previously upgraded through inclusion of serum sodium (Na) concentrations (MELD-Na). However, MELD-Na may underestimate complications arising from portal hypertension or infection. The von Willebrand factor (vWF) antigen (vWF-Ag) correlates with portal pressure and seems capable of predicting complications in patients with cirrhosis. Accordingly, this study aimed to evaluate vWF-Ag as an adjunct surrogate marker for risk stratification on the waiting list for OLT. APPROACH AND RESULTS Hence, WF-Ag at time of listing was assessed in patients listed for OLT. Clinical characteristics, MELD-Na, and mortality on the waiting list were recorded. Prediction of 3-month waiting-list survival was assessed by receiver operating characteristics and net reclassification improvement. Interestingly, patients dying within 3 months on the waiting list displayed elevated levels of vWF-Ag (P < 0.001). MELD-Na and vWF-Ag were comparable and independent in their predictive potential for 3-month mortality on the waiting list (area under the curve [AUC], vWF-Ag = 0.739; MELD-Na = 0.764). Importantly, a vWF-Ag cutoff at 413% identified patients at risk for death within 3 months of listing with a higher odds ratio (OR) than the previously published cutoff at a MELD-Na of 20 points (vWF-Ag, OR = 10.873, 95% confidence interval [CI], 3.160, 36.084; MELD-Na, OR = 7.594, 95% CI, 2.578, 22.372; P < 0.001, respectively). Ultimately, inclusion of vWF-Ag into the MELD-Na equation significantly improved prediction of 3-month waiting-list mortality (AUC, MELD-Na-vWF = 0.804). CONCLUSIONS A single measurement of vWF-Ag at listing for OLT predicts early mortality. Combining vWF-Ag levels with MELD-Na improves risk stratification and may help to prioritize organ allocation to decrease waiting-list mortality.
Collapse
Affiliation(s)
- Georg P. Györi
- Division of TransplantationDepartment of SurgeryMedical University of ViennaGeneral Hospital ViennaViennaAustria
| | - David Pereyra
- Division of General SurgeryDepartment of SurgeryMedical University of ViennaGeneral Hospital ViennaViennaAustria
| | - Benedikt Rumpf
- Division of General SurgeryDepartment of SurgeryMedical University of ViennaGeneral Hospital ViennaViennaAustria
| | - Hubert Hackl
- Division of Bioinformatics, BiocenterMedical University of InnsbruckInnsbruckAustria
| | - Christoph Köditz
- Division of General SurgeryDepartment of SurgeryMedical University of ViennaGeneral Hospital ViennaViennaAustria
| | - Gregor Ortmayr
- Division of General SurgeryDepartment of SurgeryMedical University of ViennaGeneral Hospital ViennaViennaAustria
| | - Thomas Reiberger
- Division of Gastroenterology and HepatologyDepartment of Internal Medicine IIIMedical University of ViennaGeneral Hospital ViennaViennaAustria
| | - Michael Trauner
- Division of Gastroenterology and HepatologyDepartment of Internal Medicine IIIMedical University of ViennaGeneral Hospital ViennaViennaAustria
| | - Gabriela A. Berlakovich
- Division of TransplantationDepartment of SurgeryMedical University of ViennaGeneral Hospital ViennaViennaAustria
| | - Patrick Starlinger
- Division of General SurgeryDepartment of SurgeryMedical University of ViennaGeneral Hospital ViennaViennaAustria
| |
Collapse
|
2
|
Giustiniano E, Procopio F, Morenghi E, Gollo Y, Rocchi L, Ruggieri N, Lascari V, Torzilli G, Cecconi M. Renal resistive index as a predictor of postoperative complications in liver resection surgery. Observational study. J Clin Monit Comput 2020; 35:731-740. [PMID: 32430788 DOI: 10.1007/s10877-020-00529-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Accepted: 05/13/2020] [Indexed: 12/25/2022]
Abstract
Mortality after liver surgery reduced during the last three decades to less than 2%, but post-operative morbidity occurs in 20-50% of cases. Patients are often considered eligible for post-operative intensive-care unit (ICU) admission. Predicting which patients that are at higher risk could lead to a more precise perioperative management. We investigated whether renal resistive index (RRI), alone or along with other items, can predict post-operative complication after hepatic resection. All consecutive patients undergoing hepatectomy for primary or metastatic neoplasm at our Institution between February 2015 and March 2017 were enrolled. They received RRI measurement before entering in operative room and after awakening from general anesthesia. 183 Patients were enrolled. High surgical invasiveness, surgery time > 360 min, pre-operative RRI and postoperative serum lactate clearance < - 6%, showed to be associated with postoperative complications. Pre-operative RRI, complex liver resection, long-lasting surgery and poor lactate clearance (cLac) close to awakening from general anesthesia, all together may permit to classify the risk of post-operative adverse outcome after hepatic resection surgery.
Collapse
Affiliation(s)
- Enrico Giustiniano
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy.
| | - Fabio Procopio
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy
- Hepato-Biliary & Pancreatic Surgery Unit, Humanitas Clinical and Research Center, IRCCS, via Manzoni 56, 20089, Milan, Italy
| | - Emanuela Morenghi
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy
- Biostatistic Unit, Humanitas Clinical and Research Center, IRCCS, via manzoni 56, 20089, Milan, Italy
| | - Yari Gollo
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy
| | - Laura Rocchi
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy
| | - Nadia Ruggieri
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy
| | - Valeria Lascari
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy
| | - Guido Torzilli
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy
- Hepato-Biliary & Pancreatic Surgery Unit, Humanitas Clinical and Research Center, IRCCS, via Manzoni 56, 20089, Milan, Italy
| | - Maurizio Cecconi
- Department of Anesthesia and Intensive Care, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, 20089, Milan, Italy
| |
Collapse
|
4
|
Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther 2014; 5:156-168. [PMID: 25133044 PMCID: PMC4133441 DOI: 10.4292/wjgpt.v5.i3.156] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Revised: 02/08/2014] [Accepted: 05/08/2014] [Indexed: 02/06/2023] Open
Abstract
Patients with cirrhosis and renal failure are high-risk patients who can hardly be grouped to form precise instructions for diagnosis and treatment. When it comes to evaluate renal function in patients with cirrhosis, determination of acute kidney injury (AKI), chronic kidney disease (CKD) or AKI on CKD should be made. First it should be excluded the prerenal causes of AKI. All cirrhotic patients should undergo renal ultrasound for measurement of renal resistive index in every stage of liver dysfunction and urine microscopy for differentiation of all causes of AKI. If there is history of dehydration on the ground of normal renal ultrasound and urine microscopy the diuretics should be withdrawn and plasma volume expansion should be tried with albumin. If the patient does not respond, the correct diagnosis is HRS. In case there is recent use of nephrotoxic agents or contrast media and examination shows shock, granular cast in urinary sediment and proteinuria above 0.5 g daily, acute tubular necrosis is the prominent diagnosis. Renal biopsy should be performed when glomerular filtration rate is between 30-60 mL/min and there are signs of parenchymal renal disease. The acute renal function is preferable to be assessed with modified AKIN. Patients with AKIN stage 1 and serum creatinine ≥ 1.5 mg/dL should be at close surveillance. Management options include hemodynamic monitoring and management of fluid balance and infections, potentially driving to HRS. Terlipressin is the treatment of choice in case of established HRS, administered until there are signs of improvement, but not more than two weeks. Midodrine is the alternative for therapy continuation or when terlipressin is unavailable. Norepinephrine has shown similar effect with terlipressin in patients being in Intensive Care Unit, but with much lower cost than that of terlipressin. If the patient meets the requirements for transplantation, dialysis and transjugular intrahepatic portosystemic shunt are the bridging therapies to keep the transplant candidate in the best clinical status. The present review clarifies the latest therapeutic modalities and the proposed recommendations and algorithms in order to be applied in clinical practice.
Collapse
|
5
|
Glišić TM, Perišić MD, Dimitrijevic S, Jurišić V. Doppler assessment of splanchnic arterial flow in patients with liver cirrhosis: correlation with ammonia plasma levels and MELD score. JOURNAL OF CLINICAL ULTRASOUND : JCU 2014; 42:264-269. [PMID: 24449379 DOI: 10.1002/jcu.22135] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2013] [Revised: 10/11/2013] [Accepted: 12/16/2013] [Indexed: 06/03/2023]
Abstract
PURPOSE To assess the clinical significance of blood flow velocity and resistance index (RI) in the visceral arteries of patients with liver cirrhosis with respect to plasma ammonia (NH3) level and liver function. METHODS We included 80 patients with liver cirrhosis (58 men) and 20 healthy controls (11 men). Duplex Doppler ultrasonography was used to assess flow velocity and RI in the hepatic (HA), right (RRA), and left renal (LRA), and splenic (SA) (LA) artery. Plasma NH3 was measured by biochemistry. Liver function was assessed by MELD score (model of end-stage liver disease). RESULTS HA, LRA, and SA systolic flow velocities were greater, whereas RRA diastolic velocity was lower in patients with liver cirrhosis than in controls RI was higher in LRA, RRA, SA, and HA in patients with liver cirrhosis than in controls. NH3 levels were significantly elevated in all patients with liver cirrhosis (p < 0.05) and significantly correlated with RI of RRA, LRA, and SA. CONCLUSION We found greater renal, hepatic, and LA RI in patients with liver cirrhosis than in healthy controls. The correlation we found between elevated renal artery RI (≥0.70) and MELD score emphasizes the risk of renal dysfunction during progression of liver cirrhosis.
Collapse
Affiliation(s)
- Tijana M Glišić
- Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia, Serbia
| | | | | | | |
Collapse
|